# Edgar G. Engleman

> Edgar G. Engleman is a Series A investor at Vivo Capital backing Biotechnology. See 5 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: Angel Investor
- Fund: [Vivo Capital](https://shizune.co/investors/profile/vivo-capital)
- Location: San Francisco Bay Area, United States
- Total investments: 5
- Last investment: Jul 2020
- Lead investor: 40%
- Last updated: Sep 2026
- LinkedIn: https://www.linkedin.com/in/edgar-engleman-04b1325

Edgar G. Engleman is a Series A investor at Vivo Capital in San Francisco Bay Area focused on Biotechnology and Medical. Dr. Edgar G. Engleman is the Member Of The Board Of Directors at Capia since 2001.He is a Founding Member of Vivo Ventures, LLC (formerly BioAsia Investments).Dr. Engleman is Professor of Pathology and Medicine at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. An editor ofnumerous scientific journals and the inventor of multiple patented technologies, Dr. Engleman has authored more than 250 publications in medical and scientific journals and has trained more than 200 graduate students and postdoctoral fellows.He has co-founded a number of biopharmaceutical companies including Cetus Immune, Genelabs, National Medical Audit and Dendreon. He is the lead inventor of the technology underlying Provenge, Dendreon's cancer vaccine, which was shown to extend life for patients with metastatic prostate cancer with remarkably few side effects. Provenge is the first active immunotherapeutic agent to be approved by the FDA (in 2010).Dr. Engleman currently serves on the boards of several private biotechnology companies. He received his BA from Harvard University and his MD from Columbia University School of Medicine.

## Contacts

5 contacts available for Edgar G. Engleman: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/edgar-g-engleman?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Medical | 2 | 40% |
| Health Care | 2 | 40% |
| Genetics | 1 | 20% |
| Biopharma | 1 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 1 | 20% |
| Series D | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tranquis Therapeutics | Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide. Founded on groundbreaking neuro-immunology research from the laboratoryof Professor Edgar Engleman, MD, at Stanford University, Tranquis’ novel therapeutic approach targets underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. The company’s portfolio is comprised of small molecules which cross the blood-brain barrier, and the lead therapeutic candidate has demonstrated highly encouraging effects in challenging preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), and age-related cognitive impairment. Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer’s Disease. | $30M | Series A | Jul 09, 2020 | https://www.tranquis.com/ |
| REGENXBIO | REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologicdisorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia. | $70.5M | Series D | May 20, 2015 | http://regenxbio.com |
| Eiger BioPharmaceuticals | Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Itsstrategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients. | $14.5M | Series A | Apr 15, 2011 | http://www.eigerbio.com |
| Eiger BioPharmaceuticals | Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Itsstrategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients. | $8.3M | Series A | Feb 25, 2009 | http://www.eigerbio.com |
| CAPNIA | CAPNIA is a private company developing novel therapeutic products using its proprietary medical gas delivery system. We are targeting a number of chronic diseases treatable with topical application of well understood, safe and effective gas compounds. Our first product is entering Phase IIb clinical trials for the treatment of acute migraines andrelated symptoms. 28 million Americans and over 240 million people worldwide suffer from this debilitating condition. | $12M | Series B | May 03, 2004 | http://www.capnia.com |

5 of 5 investments shown.

## Co-investors
- [InterWest Partners](https://shizune.co/investors/profile/interwest-partners) — VC Fund, 2 deals together
- [Asset Management Ventures (AMV)](https://shizune.co/investors/profile/asset-management-ventures) — VC Fund, 1 deal together
- [Brookside Capital](https://shizune.co/investors/profile/brookside-capital) — VC Fund, 1 deal together
- [Correlation Ventures](https://shizune.co/investors/profile/correlation-ventures) — VC Fund, 1 deal together
- Hillsborough Venture — VC Fund, 1 deal together
- [QVT Financial](https://shizune.co/investors/profile/qvt-financial) — VC Fund, 1 deal together

## About Vivo Capital

VC Fund · Palo Alto, United States

The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.

5 contacts available at Vivo Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Gaurav Aggarwal | Managing Director | https://shizune.co/investors/profile/gaurav-aggarwal |
| Michael Chang | Managing Partner | https://shizune.co/investors/profile/michael-chang-2 |
| Shan Fu | Managing Partner, Co-CEO, and CEO of Asia Pacific | https://shizune.co/investors/profile/shan-fu |
| Chloe Zhang | Principal | https://shizune.co/investors/profile/chloe-zhang-1 |
| Edgar G. Engleman | Co - Founder & Managing Partner | https://shizune.co/investors/profile/edgar-g-engleman |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Edgar G. Engleman invest in?

Edgar G. Engleman invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Edgar G. Engleman?

Public channels for Edgar G. Engleman include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Edgar G. Engleman last invest?

The most recent investment recorded for Edgar G. Engleman closed in Jul 2020. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co